Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

William Marston Linehan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7983-3109; OpenAlex author ID A5107963543. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug. Co-author DOI 10.1016/j.freeradbiomed.2024.07.008↗
  2. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. Co-author DOI 10.7554/elife.46312↗

Trials 2

  1. Phase II Study of Vandetanib in Individuals With Kidney Cancer Principal investigator NCT00566995↗
  2. 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Principal investigator NCT00088374↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeffrey Brender · 2 shared papers, 2019–2024 · strength 0.29
  2. Kazutoshi Yamamoto · 2 shared papers, 2019–2024 · strength 0.29
  3. Shun Kishimoto · 2 shared papers, 2019–2024 · strength 0.29
  4. Murali Cherukuri Krishna · 2 shared papers, 2019–2024 · strength 0.29
  5. Daniel R. Crooks · 2 shared papers, 2019–2024 · strength 0.29
  6. Yasunori Otowa · 1 shared paper, 2024 · strength 0.22
  7. Mark N. Levine · 1 shared paper, 2024 · strength 0.22
  8. Tomohiro Seki · 1 shared paper, 2019 · strength 0.07
  9. peter L choyke · 1 shared paper, 2019 · strength 0.07
  10. James B. Mitchell · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.